Genetic Testing Market Size, By Test, By Application, By Technology, Industry Analysis Report, Country Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032

Description

List of Tables

Global Genetic Testing Market is set to experience robust growth through 2032 owing to the increasing adoption of genetic testing for clinical care by physicians. The growing use of genetic testing in genetic and oncology illnesses, as well as increased physician use of genetic tests in clinical treatment, is set to drive market expansion during the forecast timeframe.

The demand for genetic testing has been fueled by technological developments and the availability of new tests, which has raised patient preference for tailored medications and accelerated corporate growth. Furthermore, hefty investments in R&D studies focusing on genetic testing solutions would boost the market expansion in the coming years. Citing an instance, the government of UK announced more than USD 127.7 million to accelerate the diagnosis of rare genetic diseases in newborns. Besides, additional funding was offered to kickstart programs to improve the speed and accuracy of cancer detection and managing health inequalities.

The genetic testing market has been divided in terms of test, application, technology, and region.

Based on test, the predictive testing segment is expected to amass more than USD 1.9 billion valuation by 2032. Technological developments, combined with an increase in the prevalence of genetic illnesses, will drive the predictive testing market. High-impact rendering elements include the development of novel genetic testing methods and technologies, as well as improved efficiency and accuracy. The introduction of non-invasive prenatal testing (NIPT) or cell-free fetal DNA testing, for example, will accelerate the acceptance of genetic testing and support the market expansion.

With respect to application, the cardiovascular diseases segment is anticipated to expand significantly over the review years credited to the growing rates of inherited cardiovascular conditions including cardiomyopathy, arrhythmias, as well as high blood cholesterol. Moreover, good reimbursement provided for the detection of cardiovascular disorders is set to propel segmental growth.

In terms of technology, the molecular testing segment is poised to proliferate robustly through the forecast period. Genotyping can help with prognosis, disease diagnosis, and progression, as well as guide treatment options and response, and identify targets for gene-specific medicines.

From the regional perspective, the Europe genetic testing market is speculated to attain more than USD 9.8 billion business share by 2032. The regional market growth can be credited to the expanding presence of major players in the industry that are focusing on integrating advanced techniques within genetic testing equipment.

Product Code: 2490

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Genetic testing industry 360 degree synopsis, 2018-2032
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 Application trends
- 2.1.4 Technology trends
- 2.1.5 Regional trends

Chapter 3 Genetic Testing Industry Insights

3.1 Industry landscape
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Physician adoption of genetic tests into clinical care
  - 3.2.1.2 Technological advancements and availability of new tests
  - 3.2.1.3 Growing application of genetic testing in oncology and genetic diseases
  - 3.2.1.4 Consumer interest in personalized medicines
  - 3.2.1.5 Growing demand for direct-to-consumer genetic testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High costs of genetic testing
  - 3.2.2.2 Dearth of experienced professionals and advanced infrastructure in developing and underdeveloped economies
3.3 Growth potential analysis
- 3.3.1 By test type
- 3.3.2 By application
- 3.3.3 By technology
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Technology landscape
3.7 Policy landscape
3.8 Insurance landscape
3.9 Reimbursement scenario
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2021

4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Strategy dashboard, 2021

Chapter 5 Genetic Testing Market, By Test Type

5.1 Key test type trends
5.2 Predictive testing
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Carrier testing
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Prenatal and Newborn Testing
- 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 Diagnostic Testing
- 5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6 Pharmacogenomic testing
- 5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.7 Nutrigenomics
- 5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.8 Others
- 5.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Genetic Testing Market, By Application

6.1 Key application trends
6.2 Cancer diagnosis
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Genetic diseases
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Cardiovascular diseases
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Others
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Genetic Testing Market, By Technology

7.1 Key technology trends
7.2 Cytogenetic testing
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Biochemical testing
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Molecular testing
- 7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8 Genetic Testing Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Poland
- 8.3.7 The Netherlands
- 8.3.8 Sweden
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Thailand
- 8.4.8 Vietnam
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.5.5 Peru
- 8.5.6 Chile
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Turkey
- 8.6.5 Israel
- 8.6.6 Iran

Chapter 9 Company Profiles

9.1 23andMe, Inc.
9.2 Abbott Laboratories
9.3 Ambry Genetics (Konica Minolta)
9.4 BGI
9.5 Biocartis Group NV
9.6 bioMérieux SA
9.7 Blueprint Genetics
9.8 Cepheid (Danaher Corporation)
9.9 deCODE Genetics (Amgen)
9.10 Eurofins Scientific
9.11 Illumina, Inc.
9.12 Invitae Corporation
9.13 LabCorp (Laboratory Corporation of America Holdings)
9.14 Luminex Corporation
9.15 Myriad Genetics, Inc.
9.16 Natera, Inc.
9.17 Qiagen
9.18 Quest Diagnostics
9.19 Roche Diagnostics
9.20 Siemens Healthineers AG